DC-CIK细胞联合化疗治疗晚期结直肠癌的临床探讨

目的 探讨树突状细胞-细胞因子诱导的杀伤细胞（DC-CIK）联合化疗对晚期结直肠癌的疗效.方法 回顾性分析42例行DC-CIK细胞疗法联合化疗的晚期结直肠癌患者的临床资料,采用1：1配对的方法,选择同期单独行化疗的42例晚期结直肠癌患者作为对照组.对两组的有效率（RR）、疾病控制率（DCR）、生存期及无疾病进展时间进行观察比较.结果 DC-CIK治疗组患者的疾病控制率（DCR）明显高于化疗组（76.19％ VS 52.38％）,差异有统计学意义（P＜0.05）;治疗组的中位生存期明显高于化疗组（17.5个月VS 13.3个月）,差异有统计学意义（P=0.008）.结论 DC-CIK细胞联合化疗可以明显提高晚期结直肠癌患者的疾病控制率,延长生存期.

Objective To evaluate the effect of DC-CIK adoptive immunotherapy combined with chemotherapy in the treatment of advanced colorectal cancer. Methods We retrospectively analyzed 42 patients of advanced colorectal cancer treated with DC-CIK adoptive immunotherapy combined with chemotherapy and choose 42 patients at the same period as control treated only with chemotherapy.The response rate （ RR ） , disease control rate （ DCR ） , median overall survival time and progression-free survival time were investigated and compared between the two groups. Results The disease control rate in the DC-CIK treatment group was significantly higher than that in the chemotherapy group （ 76.19% VS 52.38% ） , and the difference was statistically significant （ P〈0.05 ） ,The median overall survival time in the DC-CIK treatment group was significantly longer than that in the chemotherapy group （ 17.5 VS 13.3months ） , and the difference was statistically significant （ P=0.008 ） . Conclusion DC-CIK adoptive immunotherapy combined with chemotherapy could significantly improve the disease control rate and the overall survival time of patients with advanced colorectal cancer.